R012JE

Prion protein related peptide library
HiPep laboratories offer various prion-protein related peptides which had been designed and prepared. These
peptides could discriminate structural changes of prion proteins and may inhibit or promote PrPSc generation. Theinteraction of these designed peptides with infectious prion obtained from mouse brain and infected mice brain
homogenate has been investigated. Furthermore, by using our novel assay method to monitor structural conversionof recombinant bovine prion protein, we have found the responsible peptides for the structural conversion frombovine brain extracts. These peptide libraries are useful tool for research on protein-structural disease.

Prion protein[Homo sapiens]

1 manlgcwmlv lfvatwsdlg lckkrpkpgg wntggsrypg qgspggnryp pqggggwgqp
61 hgggwgqphg ggwgqphggg wgqphgggwg qgggthsqwn kpskpktnmk hmagaaaaga
121 vvgglggyvl gsamsrpiih fgsdyedryy renmhrypnq vyyrpmdeys nqnnfvhdcv

181 nitikqhtvt tttkgenfte tdvkmmervv eqmcitqyer esqayyqrgs smvlfssppv
241 illisflifl ivg
Signal peptide

S1
Octa-peptide
repeat

Toxic

S2
H1

S
H2

S

GPI-signal peptide
H3

CHO CHOKKR HPP-h01
HPP-h14
HPP-h02
-sheet: S1, S2
HPP-h15
HPP-h03
HPP-PC03
-helix: H1-3
HPP-h16
HPP-h04
HPP-PC07
HPP-h17
HPP-h05*KKR had
HPP-h18
HPP-h06
HPP-PC01
been
HPP-h19
HPP-h07
HPP-PC04
HPP-PC02
added for
HPP-h20
HPP-h08
HPP-PC05
HPP-h21 enhancing
HPP-h09
HPP-PC06
HPP-h10
HPP-h22solubility
HPP-h11
HPP-h23
HPP-h12KKR
HPP-h24
HPP-h13
HPP-h25
KKR

P01: hPrP(129-142)
P02: hPrP(124-142)
P03: hPrP(114-142)
P04: hPrP(109-142)
P05: hPrP(90-142)
P06: hPrP(106-126)
P07: hPrP(135-154)
P08: hPrP(155-178)
P09: hPrP(182-195)
P10: hPrP(200-213)
P11: hPrP(215-229)
P12: hPrP(228-253RR)

attachement of
RR for solubility

Reference
Kasai, K., Hirata, A., Ohyama,T., Nokihara, K., Yokoyama, T.,
Mohri, S. Novel assay withfluorescence-labelled PrP
peptides for differentiating Ltype atypical and classical BSEs,
and scrapie, FEBS Lett. 2012,586, 325-329.

Characteristic differences of prions may account for the conformational diversity of the pathogenic isoform of prion protein(PrPSc). We applied a protein detection procedure by using fluorescent labeled peptides for detecting PrPSc. Five prion protein(PrP) related peptides were found to change significantly their fluorescent intensities with prion-affected animal samples. Theirreactivity was different among atypical L-BSE, classical BSE and scrapie. The pull-down assay revealed that they precipitated
PrPSc specifically. These findings suggest that fluorescent intensity changes depend on peptide PrPSc binding. This novel
approach may distinguish the fine structural differences in PrPSc, which were not detected by the pull-down assay.
Hirata, A., Yajima, S., Yasuhara, T., Nokihara, K. Structural Conversion Rate Changes of Recombinant Bovine Prion by
Designed Synthetic Peptides, Int. J. Pept. Res. Ther. 2012, 18, 1-9.
An understanding of structural changes and self-assembly of proteins are thought to involve specific peptide-peptide
interactions and it will contribute to the development of therapeutic agents and diagnosis for the detection of conformational
diseases such as bovine spongiform encephalopathy or human Creutzfeld-Jakob disease. We hypothesize that certain peptides
may contribute to the conformational change of prion proteins. In contrast to the known effects of beta-sheet breaker
peptides, we suggest a possible reverse phenomenon may exist in which certain peptides may induce or enhance putative
beta-sheet structures. Hence designed human prion protein related peptides may be useful tools for the investigation of thishypothesis. Our paper describes the discovery of prion-related peptides which influence structural conversion of recombinantbovine prion protein.
Nokihara, K., Yajima, S., Hirata, A., Sogon, T., Yasuhara, T. Characterization of peptides obtained from digests of bovine brain
which accelerate structural conversions of the recombinant bovine prion protein, FEBS Lett. 2013, 587, 673-576.

HiPep Laboratories, Nakatsukasa-cho 486-46, Kamigyo-ku, Kyoto, 602-8158, Japan
Tel +81-75-813-2101 E-mail: PepTenChip@hipep.jp URL: http://www.hipep.jp/1R012JE

プリオンタンパク質関連ペプチドライブラリー
背景：平成19年度～23年度までの5年間、（独）農業・食品産業技術総合研究機構生物系特定産業技術研究支援センター「生物系産業創出のための異分野融合研究支援事業」を進めました。当該研究成果にもとづいて構築した「ヒトプリオンペプチド断片ペプチドライブラリー」をご提供させていただきます。弊社では、BSE等プリオン病の発症前診断を可能とするバイオチップの開発研究を行い、プリオン株の種類を判別する新しいアッセイ方法も確立しました 。さらに、プリオンタンパク質の構造変換速度に影響を与えるペプチドを発見しました（論文参照）。近年、プリオンタンパク質がアルツハイマー病において神経細胞を損傷させる際の原因物質候補として注目されており、分子レベルでの研究が進められております。プ
リオンタンパク質の断片ペプチドは、人獣共通感染症としてのプリオン病の治療薬や診断ツールとして重要なだけでなく、今後罹患率が高まると予想されている、アルツハイマー病の治療薬の開発・研究にもお役に立てるものと考えております。
参考文献
Kasai, K., Hirata, A., Ohyama, T., Nokihara, K., Yokoyama, T., Mohri, S. Novel assay with fluorescence-labelled PrP peptides fordifferentiating L-type atypical and classical BSEs, and scrapie, FEBS Lett. 2012, 586, 325-329.
プリオンタンパク質関連ペプチドライブラリーのうち、h01/02は定型BSE感染牛、h03/11は非定型BSE感染牛、h06はスクレイピー感染羊・マウス脳乳剤と特異的に反応した。一方、プルダウンアッセイでは上記の5ペプチドはすべての異常プリオン蛋白質（PrPSc）と結合し、プリオンの由来や種特異性は認められなかった（図）。また、これらのことから、上記ペプチドを用いたアッセイでは、プリオンの種類、具体的には定型BSE（C-BSE）、非定型BSE（L-BSE）、スクレイピーのPrPScについて識別することができることが判明した。

2Hirata, A., Yajima, S., Yasuhara, T., Nokihara, K. Structural Conversion Rate Changes of Recombinant Bovine Prion by
Designed Synthetic Peptides Int. J. Pept. Res. Ther. 2012, 18, 1-9.
プリオンタンパク質（PrP）関連ペプチドライブラリーを利用したPrPの構造変換解析を行った。蛍光強度解析から明らかになったことは、構造変換が始まるまでの時間（ラグタイム）に差がでるという点であった。興味深いことに、PrPにおいてToxic領域として知られている部分を含むペプチドは、ラグタイムが短くリコンビナントウシPrP（rbPrP）の構造変換を早期に誘起することが明らかとなり、Toxicityとの相関を伺わせる結果であった。これらの結果から、ペプチドの種類によりラグタイムに多様性があることから、rbPrPとペプチドとの相互作用に同様の多様性があることを示唆している。すなわち、これらのペプチドを組み合わせることで、バイオチップにおいて蛍光強度をバーコード化し、PrPの構造変換を検出することが十分可能であることを示した。
Nokihara, K., Yajima, S., Hirata, A., Sogon, T., Yasuhara, T. Characterization of peptides obtained from digests of bovine brain
which accelerate structural conversions of the recombinant bovine prion protein, FEBS Lett. 2013, 587, 673-576.
Nokihara, K., Yajima, S., Hirata, A. Design and syntheses of peptides which induce or enhance structural changes ofrecombinant bovine prion protein (rbPrP) and discovery of peptides from bovine brain which accelerate structural conversionsof rbPrP, Prion. 2014, 8, 117-118.
N末端Ac、C末端ビオチン
N末端FAM、C末端ビオチン
N末端TAMRA、C末端ビオチン
N末端TAMRA、C末端アミド
N末端TAMRA、C末端システイン

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HiPep Laboratories, Nakatsukasa-cho 486-46, Kamigyo-ku, Kyoto, 602-8158, Japan
Tel +81-75-813-2101 E-mail: PepTenChip@hipep.jp URL: http://www.hipep.jp/

R012JE

Prion protein related peptide library
Seq.

Modification

P/NSeq.

Modification

P/N

HamsterPrP
113-141

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-PC01-AB
HPP-PC01-FB
HPP-PC01-TB
HPP-PC01-TA
HPP-PC01-TC

HumanPrP
51-65

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h06-AB
HPP-h06-FB
HPP-h06-TB
HPP-h06-TA
HPP-h06-TC

Mouse
PrP
23-33

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-PC02-AB
HPP-PC02-FB
HPP-PC02-TB
HPP-PC02-TA
HPP-PC02-TC

HumanPrP
61-75

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h07-AB
HPP-h07-FB
HPP-h07-TB
HPP-h07-TA
HPP-h07-TC

Mouse
PrP
98-110N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-PC03-AB
HPP-PC03-FB
HPP-PC03-TB
HPP-PC03-TA
HPP-PC03-TC

Human
PrP
71-85

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h08-AB
HPP-h08-FB
HPP-h08-TB
HPP-h08-TA
HPP-h08-TC

Mouse
PrP
136-158

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-PC04-AB
HPP-PC04-FB
HPP-PC04-TB
HPP-PC04-TA
HPP-PC04-TC

Human
PrP
81-95

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h09-AB
HPP-h09-FB
HPP-h09-TB
HPP-h09-TA
HPP-h09-TC

Human
PrP
23-30

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-PC05-AB
HPP-PC05-FB
HPP-PC05-TB
HPP-PC05-TA
HPP-PC05-TC

Human
PrP
91-105N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h10-AB
HPP-h10-FB
HPP-h10-TB
HPP-h10-TA
HPP-h10-TC

Human
PrP
19-30,C22S

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-PC06-AB
HPP-PC06-FB
HPP-PC06-TB
HPP-PC06-TA
HPP-PC06-TC

Human
PrP
101-115

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h11-AB
HPP-h11-FB
HPP-h11-TB
HPP-h11-TA
HPP-h11-TC

HumanPrP100-111

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-PC07-AB
HPP-PC07-FB
HPP-PC07-TB
HPP-PC07-TA
HPP-PC07-TC

Human
PrP
111-125

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h12-AB
HPP-h12-FB
HPP-h12-TB
HPP-h12-TA
HPP-h12-TC

Human
PrP1-12KKR,
C6S

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h01-AB
HPP-h01-FB
HPP-h01-TB
HPP-h01-TA
HPP-h01-TC

Human
PrP
121-135

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h13-AB
HPP-h13-FB
HPP-h13-TBHPP-h13-TA
HPP-h13-TC

Human
PrP
11-25,C22S

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h02-AB
HPP-h02-FB
HPP-h02-TB
HPP-h02-TA
HPP-h02-TC

Human
PrP
131-145

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h14-AB
HPP-h14-FB
HPP-h14-TB
HPP-h14-TA
HPP-h14-TC

Human
PrP
21-35,C22S

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h03-AB
HPP-h03-FB
HPP-h03-TB
HPP-h03-TA
HPP-h03-TC

HumanPrP
141-155

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h15-AB
HPP-h15-FB
HPP-h15-TB
HPP-h15-TA
HPP-h15-TC

HumanPrP
31-45

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h04-AB
HPP-h04-FB
HPP-h04-TB
HPP-h04-TA
HPP-h04-TC

HumanPrP
151-165

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h16-AB
HPP-h16-FB
HPP-h16-TB
HPP-h16-TA
HPP-h16-TC

HumanPrP
41-55

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h05-AB
HPP-h05-FB
HPP-h05-TB
HPP-h05-TA
HPP-h05-TC

HumanPrP
161-175

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h17-AB
HPP-h17-FB
HPP-h17-TB
HPP-h17-TA
HPP-h17-TC

HiPep Laboratories, Nakatsukasa-cho 486-46, Kamigyo-ku, Kyoto, 602-8158, Japan3

Tel +81-75-813-2101 E-mail: PepTenChip@hipep.jp URL: http://www.hipep.jp/

R012JE

プリオンタンパク質関連ペプチドライブラリー
Sequence

Modification

P/N

Sequence

Modification

P/N

Human
PrP
171-185,
C179S

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h18-AB
HPP-h18-FB
HPP-h18-TB
HPP-h18-TA
HPP-h18-TC

Human
PrP
211-225,C214S

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h22-AB
HPP-h22-FB
HPP-h22-TB
HPP-h22-TA
HPP-h22-TC

Human
PrP
181-195

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini AmideN-termini TAMRA, C-termini Cysteine

HPP-h19-AB
HPP-h19-FB
HPP-h19-TB
HPP-h19-TA
HPP-h19-TC

HumanPrP
221-235

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h23-AB
HPP-h23-FB
HPP-h23-TB
HPP-h23-TA
HPP-h23-TC

HumanPrP
191-205

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h20-AB
HPP-h20-FB
HPP-h20-TB
HPP-h20-TA
HPP-h20-TC

HumanPrP
231-242
KKR

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h24-AB
HPP-h24-FB
HPP-h24-TB
HPP-h24-TA
HPP-h24-TC

Human
PrP
201-215,
C214S

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h21-AB
HPP-h21-FB
HPP-h21-TB
HPP-h21-TA
HPP-h21-TC

HumanPrP
241-252
KKR

N-termini Ac, C-termini Biotin
N-termini FAM, C-termini Biotin
N-termini TAMRA, C-termini Biotin
N-termini TAMRA, C-termini Amide
N-termini TAMRA, C-termini Cysteine

HPP-h25-AB
HPP-h25-FB
HPP-h25-TB
HPP-h25-TA
HPP-h25-TC

注文番号

アミノ酸配列*凝集性が高く難精製ペプチドであったが、自社開発の手法で精製できた。カウンターイオンはTFA

HPP-P01

MLGSAMSRPIIHFG (human PrP129-142)

HPP-P02

GLGGYMLGSAMSRPIIHFG (human PrP124-142)

HPP-P03GAAAAGAVVGGLGGYMLGSAMSRPIIHFG (human PrP114-142)

HPP-P04

MKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFG (human PrP109-142)

HPP-P05

GQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFG

single¥ 200,000/peptide~5 ¥ 150,000/peptide~
10 ¥ 120,000/peptide~
20 ¥ 90,000/peptide~
50 ¥ 50,000/peptide~
all ca ¥30,000/peptide~
Each peptide is 1 mM in DMSO 100 mL
stock solution*1.5 mL microtube

HPP-P06

KTNMKHMAGAAAAGAVVGGLG (human PrP106-126)

Upon request tailor made sequence;
Lyophilized peptides; aliquoted in a 96
well-plate can be available.

HPP-P07

SRPIIHFGSDYEDRYYRENM (human PrP135-154)

単品¥ 200,000/peptide~

HPP-P08

HRYPNQVYYRPMDEYSNQNNFVHD (human PrP155-178)

5種¥ 150,000/peptide~

HPP-P09ITIKQHTVTTTTKG (human PrP182-195)

HPP-P10ETDVKMMERVVEQM (human PrP200-213)

20種 ¥ 90,000/peptide~
50種 ¥ 50,000/peptide~

HPP-P11ITQYERESQAYYQRG (human PrP215-229)

HPP-P12RGSSMVLFSSPPVILLISFLIFLIVG-RR (human PrP228-253 RR)

HPP-SHYSNQNNF-VNITIKQHTVTTTTKG-NH2 [human PrP(169-175)+(180-195)]

HPP-A01

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT (Amyloid  1-43)

HPP-A02

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (Amyloid  1-42)

HPP-A03

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV (Amyloid  1-40)

HPP-A04

LVFFAEDVGSNKGAIIGLMVGGVVIA (Amyloid  17-42)

HPP-A05

AEDVGSNKGAIIGLMVGGVVIA (Amyloid  21-42)

HPP-A06

LVFFAEDVGSNKGAIIGLMVGGVV (Amyloid  17-40)

HPP-A07

DAEFRHDSGYEVHHQKLVFF (Amyloid  1-20)(human PrP90-142)

10種 ¥ 120,000/peptide~

全種 ca ¥30,000/peptide~
各種1 mM peptide in DMSO
100 mL ストックソリューション
*1.5 mLマイクロチューブに分注
粉末サンプルでの提供も可能、価格はご希望の量に合わせて都度見積
96 ウエルタイタープレートへの分注も対応*We have developed novel purification
methods for structured peptides, suchas peptides having difficult sequences.
Refer also Column Informationwww.hipep.jp/eng.
*Counter ion of peptide is TFA

標識化酸配列改変の場合は、弊社受託合成規定を適用（お見積）
単なる依頼による受託作業ではなく、研究の上流から下流までを視野に入れた研究者の立場からの支援が可能
必要に応じ秘密保持契約等を締結。共同・受託研究開発（契約料+成功報酬／成果は共有）、コンサルテーション（成果はクライエントが保有）も対応

HiPep Laboratories, Nakatsukasa-cho 486-46, Kamigyo-ku, Kyoto, 602-8158, Japan
Tel +81-75-813-2101 E-mail: PepTenChip@hipep.jp URL: http://www.hipep.jp/4